Klaria Pharma Holding AB (publ) ("Klaria" or the "Company") today announces the final outcome of the Company's rights issue of units, which was resolved upon by the extraordinary general meeting held on 5 October 2026 and for which the subscription period ended on 6 November 2026 (the "Rights Issue"). Subscriptions with and without the exercise of unit rights amounted to approximately 61.4 per cent of the Rights Issue, equivalent to approximately SEK 90.6 million. In addition, Vator Securities AB ("Vator") is subscribing for units for a total of approximately SEK 20.5 million pursuant to its underwriting commitment. The Rights Issue will therefore raise approximately SEK 111.1 million for Klaria before issue costs, of which approximately SEK 37.3 million will be paid by way of set-off against claims on the Company.
"We would like to thank our existing shareholders and new investors for their confidence. The proceeds strengthen the Company's financial position, settle short-term liabilities and enable us to execute our commercial strategy," says Fredrik Hübinette, Chairman of the Board of Klaria.
The Rights Issue comprised a maximum of 61,494,038 units. Each unit consists of four (4) new shares and one (1) warrant of series TO1 issued free of charge. The subscription price was SEK 2.40 per unit, equivalent to SEK 0.60 per share.
| Outcome | Units | SEK million | Percentage of the Rights Issue |
| Subscriptions with the exercise of unit rights | 14,333,481 | 34.4 | 23.3% |
| Subscriptions without the exercise of unit rights | 23,423,099 | 56.2 | 38.1% |
| Total subscriptions | 37,756,580 | 90.6 | 61.4% |
| Vator's subscription pursuant to its underwriting commitment | 8,537,585 | 20.5 | 13.9% |
| Total subscribed and allotted | 46,294,165 | 111.1 | 75.3% |
Of the total issue proceeds, approximately SEK 37.3 million will be paid by way of set-off against claims on the Company. Cash proceeds will therefore amount to approximately SEK 73.8 million before issue costs and repayment of loans.
Issue costs are estimated at approximately SEK 10 million, excluding underwriting remuneration.
Units subscribed for without the exercise of unit rights have been allotted in accordance with the allotment principles set out in the prospectus. Notification of allotment will be provided by means of a contract note, and payment must be made in accordance with the instructions in the contract note. Investors who subscribed through a nominee will receive notification in accordance with the nominee's procedures.
The Rights Issue will result in the issuance of 185,176,660 shares and 46,294,165 warrants of series TO1. Upon registration with the Swedish Companies Registration Office, the number of shares will increase from 245,976,152 to 431,152,812, and the share capital will increase by approximately SEK 3,086,277.72, from approximately SEK 4,099,602.61 to approximately SEK 7,185,880.33. For shareholders who did not participate in the Rights Issue, dilution will amount to approximately 43.0 per cent of the shares and votes, calculated on the basis of the number of shares outstanding following the Rights Issue.
Full exercise of the TO1 warrants issued in the Rights Issue will result in an additional 46,294,165 shares and may provide the Company with further proceeds of approximately SEK 27.8 million before issue costs. The additional dilution would amount to approximately 9.7 per cent, calculated on the basis of the number of shares outstanding following the Rights Issue and full exercise of the warrants. These calculations exclude any separate issue of units as remuneration for underwriting commitments.
Each warrant of series TO1 entitles the holder to subscribe for one (1) new share at SEK 0.60 during any of the following exercise periods: 22-26 November 2027, 17-21 April 2028, 9-13 October 2028, 5-9 March 2029 and 17-31 October 2029. The subscription price and the number of shares may be adjusted in accordance with the full terms and conditions of the warrants. Warrants not exercised by the end of the final exercise period will expire without value.
Trading in paid subscribed units (Sw. betalda tecknade units, "BTU") on Nasdaq First North Growth Market is expected to continue up to and including 24 November 2026. Following registration with the Swedish Companies Registration Office, which is expected to take place on or around 24 November 2026, the BTU will be converted into shares and warrants of series TO1. The Company intends to apply for admission to trading of the TO1 warrants on Nasdaq First North Growth Market, with the first day of trading expected to be on or around 30 November 2026.
Advisers
Carlsquare AB is acting as financial adviser and Advokatfirman Glimstedt Stockholm AB as legal adviser to Klaria in connection with the Rights Issue. Vator Securities AB is acting as issuing agent and underwriter. Advokatfirman Lindahl KB and Pro Rata AB are acting as advisers to Carlsquare.
For further information, please contact
Fredrik Hübinette, Chairman of the Board
Email: info@klaria.com
Telephone: 08-446 42 99
Website: www.klaria.com
About Klaria
Klaria Pharma Holding AB (publ) develops and commercialises pharmaceuticals through its subsidiary Klaria AB. Its business is based on a patented alginate film that adheres to the oral mucosa for drug delivery. The Company's shares are traded under the ticker symbol KLAR on Nasdaq First North Growth Market. FNCA Sweden AB is the Company's Certified Adviser (info@fnca.se, 08-528 00 399).
Disclosure
This information is information that Klaria Pharma Holding AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, on 12 November 2026 at 18:45 CET.